Evotec SE and Takeda Pharmaceutical Company Ltd have entered a strategic drug discovery collaboration potentially worth $850m.
Under the agreement, Evotec will develop at least five small molecule discovery programmes against targets identified by Takeda in oncology, gastroenterology, neuroscience and rare diseases. Takeda will have the option to assume responsibility at lead series and upon Evotec delivering a pre-clinical candidate.
Under the terms of the collaboration, Takeda will pay Evotec an undiclosed upfront fee to get access to its platforms. Additionally, Evotec is eligible to receive pre-clinical, clinical, and commercial milestones that can total in excess of $170 m per programme as well as tiered royalties on future sales.
Evotec and Takeda enter drug discovery deal
Latest NewsEvotec SE and Takeda Pharmaceutical Company Ltd have entered a strategic drug discovery collaboration potentially worth $850m.
Under the agreement, Evotec will develop at least five small molecule discovery programmes against targets identified by Takeda in oncology, gastroenterology, neuroscience and rare diseases. Takeda will have the option to assume responsibility at lead series and upon Evotec delivering a pre-clinical candidate.
Under the terms of the collaboration, Takeda will pay Evotec an undiclosed upfront fee to get access to its platforms. Additionally, Evotec is eligible to receive pre-clinical, clinical, and commercial milestones that can total in excess of $170 m per programme as well as tiered royalties on future sales.
BioBLU® 10c Single-Use Vessel
ProductsThe important link for bioprocess scale-up!
EMA greenlights new medicines
Latest NewsAt its September meeting, the EMA’s CHMP recommended three innovative medicines for EU market approval.
New malaria lead kills 99.9% of pathogens
Latest NewsDutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Versantis raises CHF16m in Series B financing
Latest NewsSwiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
Lundback swallows migraine drug maker Alder
Latest NewsDanish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (€1.76bn) to acquire Alder BioPharmaceuticals Inc.
PFF Group NV acquires stake in Autolus Therapeutics
Latest NewsPrague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
Elcin Barker Ergun becomes Menarini CEO
AppointmentsThe Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.
Researchers identify CTLA-4 response marker
Latest NewsGerman and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Inotrem SA raises €39m to provide POC for nangibotide
Latest NewsFrench biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.